United States: Species Are Unpatentable When Prior Art Disclosures Describe The Genus Such That A Person Of Ordinary Skill In The Art Would Be Able To Envision Every Member Of The Class

In AbbVie Inc. v. Mathilda & Terence Kennedy Institute of Rheumatology Trust, No. 13-1545 (Fed. Cir. Aug. 21, 2014), the Federal Circuit affirmed the district court's finding of obviousness-type double patenting. 

The Mathilda and Terence Kennedy Institute of Rheumatology Trust ("Kennedy") is the owner of U.S. Patent Nos. 6,270,766 ("the '766 patent") and 7,846,442 ("the '442 patent"), directed to methods of treating rheumatoid arthritis by co-administering a disease-modifying antirheumatic drug and an antibody.  The '766 patent claims a method of co-administering the Tumor Necrosis Factor Alpha ("TNFα") antibody and methotrexate.  After the '766 patent issued, Kennedy obtained the '442 patent, which contains "method of treatment" claims.  While Kennedy admits that the claims of the '442 patent are encompassed by the '766 patent, the claims of the '442 patent are directed towards a more specific patient group.  The '766 patent previously expired on October 8, 2012, and the '442 patent, which claimed a later priority date than the '766 patent, expires on August 21, 2018.

In 2002, AbbVie Inc. and AbbVie Biotechnology Limited (collectively "AbbVie") licensed the '766 patent and obtained FDA approval to sell Humira, an anti-TNFα antibody, for use either alone or in combination with methotrexate, for the treatment of rheumatoid arthritis.  After the '442 patent issued in 2010, Kennedy demanded that AbbVie pay royalties under the '442 patent in order to continue sales of Humira.  In response, AbbVie sued Kennedy for DJ that the claims of the '442 patent were invalid over the '766 patent under the doctrine of obviousness-type double patenting.  After conducting a bench trial, the district court found that the '442 patent covered the same invention as the '766 patent and was invalid over the claims of the '766 patent for obviousness-type double patenting.  The district court entered a partial final judgment, under Fed. R. Civ. P. 54(b), in favor of AbbVie, and Kennedy appealed.

"Thus, species are unpatentable when prior art disclosures describe the genus containing those species such that a person of ordinary skill in the art would be able to envision every member of the class."  Slip op. at 24.

The Federal Circuit first turned to Kennedy's argument that the statutory and policy rationales for the doctrine of obviousness-type double patenting no longer exist and, thus, the doctrine should be discarded.  Specifically, "[n]ow that the patent term is measured from the earliest claimed priority date, as opposed to the date of issuance, Kennedy contends that the submarine patent problem no longer exists and that the [Uruguay Round Agreements Act] amendment vitiated the policy basis for the doctrine of obviousness-type double patenting."  Slip op. at 11.  The Court, however, disagreed, explaining that Kennedy ignored that the doctrine is also designed to prevent inventors from obtaining a second, later expiring patent on the same invention, which is another "crucial purpose of the doctrine."  Id.  Noting its recent decision in Gilead Sciences, Inc. v. Natco Pharma Ltd., 753 F.3d 1208 (Fed. Cir. 2014), the Court stated, "We now make explicit what was implicit in Gilead:  the doctrine of obviousness-type double patenting continues to apply where two patents that claim the same invention have different expiration dates."  Slip op. at 13.  Indeed, the Court explained, "Kennedy is not entitled to an extra six years of monopoly solely because it filed a separate application unless the two inventions are patentably distinct."  Id.

The Court next addressed whether the doctrine of obviousness-type double patenting applied in the instant case.  Noting that obviousness-type double patenting is a two-step inquiry, the Court first turned to the claim construction of the terms "co-administration" and "active disease" as used in both the '766 and '442 patents. 

As to the term "co-administration," the Court found that, by way of claim construction, Kennedy was attempting to enlarge the scope of the '766 patent while simultaneously narrowing the scope of the '442 patent.  Kennedy took the position that the district court's claim construction of the term "co-administration" erroneously excluded a fourth form of co-administration.  The Court, noting that the specification confirmed the correctness of the district court, found that "[t]he specification never uses the term 'co-administering' to refer to patients who only received the antibody after discontinuing treatment with methotrexate."  Id. at 14.  Indeed, the Court explained, the '766 patent's specification "makes clear that the invention described in the claims is limited to concomitant and adjunctive use."  Id.  Kennedy also argued that the principle of claim differentiation favored its interpretation that claim 8 encompassed embodiments where "single doses of either the antibody or methotrexate are delivered to patients," whereas claim 9 demonstrated that "the only additional limitation is that the anti-TNFα antibody must be administered in a series of doses separated by intervals of days or weeks."  Id. at 18 (citation and internal quotation marks omitted).  The Court did not find Kennedy's argument persuasive because it found that claim 9 does not disclose discontinuation of methotrexate and that the administration of methotrexate is assumed to be ongoing with the single or multiple antibody doses.  Thus, the Federal Circuit found that the specification and claims of the '766 patent supported the district court's correct interpretation of the term "co-administration."

The Court then assessed the district court's claim construction of the term "active disease."  Kennedy contended that the '442 patent provided an explicit definition for the term "active disease."  In support of this contention, Kennedy relied on the prosecution history and the examiner's indefiniteness rejection of the '442 patent for failing to define the term "active disease."  Kennedy provided an explanation that after it pointed to a particular portion of the specification as providing a more specific definition of the term "active disease" during prosecution, the examiner allowed the '442 patent's claims.  AbbVie argued that the particular quoted portion of the specification set forth two definitions and, thus, the inventors could not be viewed as having acted as their own lexicographers.  The Court, however, assumed, without deciding, that Kennedy's proposed construction for "active disease" was correct.  Accordingly, the Court stated that, in the second step of the obviousness-type double patenting inquiry, it "must decide whether a patent that claims to treat a subset of patients with more severe rheumatoid arthritis (the '442 patent) is an obvious variant of a patent that claims treatment of rheumatoid arthritis patients generally (the '766 patent)."  Id. at 21.

Turning to the obviousness inquiry in the second step of its analysis, the Federal Circuit provided a discussion of the law of obviousness-type double patenting and found that "it is clear that a reader of the '766 patent could have easily envisioned a species limited to sicker patients.  The district court was correct in concluding that the species of the '442 patent was not patentably distinct from the genus of the '766 patent."  Id. at 24.  The Court also addressed Kennedy's claim that the species had unexpected results, but found that such a claim was unsupported.  The Court explained that to assess whether the '442 patent yielded unexpected results, the Court had to assess what results were expected at the time the '766 patent application was filed.  The Court concluded that the '442 patent merely claimed the known utility of the '766 patent and did not claim a species with unexpected results.  The Court also acknowledged Kennedy's argument that the '766 patent's disclosures could not be used to determine whether the results of the '442 patent were unexpected because doing so would be tantamount to treating the disclosures of the '766 patent as prior art.  The Court explained that while "a reference patent's specification cannot be used as prior art in an obviousness-type double patenting analysis," "it is also well settled that we may look to a reference patent's disclosures of utility to determine the question of obviousness."  Id. at 26 (citations omitted).  Because the Court determined that the '442 patent did not claim a species manifesting unexpected results, the Court concluded that the '442 patent would have been obvious over the '766 patent.

Accordingly, the Federal Circuit affirmed the district court's finding that the '442 patent was invalid for obviousness-type double patenting in light of the '766 patent and awarded costs to AbbVie.

Judges:  Dyk (author), Wallach, Chen

[Appealed from S.D.N.Y., Judge Crotty]

This article previously appeared in Last Month at the Federal Circuit, September 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
27 Nov 2017, Seminar, London, UK

Finnegan partner Anthony Tridico will present “U.S. Patent Case Law Update” at the Chartered Institute of Patent Attorneys’ annual Patent Case Law Review.

28 Nov 2017, Seminar, Milan, Italy

Finnegan partner John Paul will present “Internet of Things: Patent Liability, Enforcement and Licensing” and will join the Mock WIPO Mediation at International Technology Transfer—Licensing and ADR, co-hosted by Licensing Executives Society and World Intellectual Property Organization.

29 Nov 2017, Seminar, Tel Aviv, Israel

Finnegan is a platinum sponsor IVC Research Center’s start-up forum, “The Most Promising Start Ups for 2017 – A Synergy of Big Data, Artificial Intelligence, Machine Vision and IoT.”

 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.